北京市春立正达医疗器械股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中 国公司。该公司主要产品包括关节假体产品、脊柱类植入产品、创伤类产品、运动医学类产品、富血小 板血浆（PRP）产品、口腔类产品、手术机器人产品。关节假体产品涵盖髋、膝、肩、肘四大人体关 节。该公司产品销往国内外市场。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，1月29日南向资金减持38.52万股春立医疗（01858.HK）。近5个交易日中，获南向资金 减持的有3天，累计净减持24.1万股。近20个交易日中，获南向资金减持的有11天，累计净减持300.93万 股。截至目前，南向资金持有春立医疗（01858.HK）4210.56万股，占公司已发行普通股的44.25%。 ...

Core Insights - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 21,200 shares on January 23 [1] - Over the past five trading days, there have been five days of net increases in holdings, totaling 995,300 shares [1] - In the last twenty trading days, there were eight days of net reductions, amounting to 2,141,500 shares [1] - Currently, southbound funds hold 42,367,800 shares of Chuangli Medical, representing 44.52% of the company's issued ordinary shares [1] Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. primarily engages in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow [1] - The company's products are sold in both domestic and international markets [1]

Group 1 - The core viewpoint of the article highlights the recent increase in southbound capital holdings in Chunli Medical (01858.HK), with a net increase of 113,800 shares on January 22 [1] - Over the past five trading days, Chunli Medical has seen an increase in southbound capital for four days, totaling a net increase of 865,300 shares [1] - In the last twenty trading days, there were eight days of net reduction in southbound capital, amounting to a total decrease of 1,949,000 shares [1] Group 2 - As of now, southbound capital holds 42,346,600 shares of Chunli Medical, representing 44.5% of the company's total issued ordinary shares [1] - Chunli Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with key products including joint prosthetics, spinal implants, trauma products, sports medicine products, PRP products, oral products, and surgical robots [1] - The company's joint prosthetic products cover major human joints such as hip, knee, shoulder, and elbow, and its products are sold in both domestic and international markets [1]

Group 1 - The core viewpoint of the article highlights the recent trading activity of southbound funds in Spring Medical (01858.HK), indicating a mixed trend with both increases and decreases in holdings [1] - Southbound funds increased their holdings by 368,800 shares on January 19, while over the past five trading days, there were three days of net reductions totaling 505,000 shares [1] - Over the last 20 trading days, there were ten days of net reductions, amounting to a total of 2,725,500 shares [1] Group 2 - As of now, southbound funds hold 41,741,300 shares of Spring Medical, which represents 43.86% of the company's total issued ordinary shares [1] - Spring Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with key products including joint prosthetics, spinal implants, trauma products, sports medicine products, PRP products, oral products, and surgical robots [1] - The company's joint prosthetic products cover major human joints such as hip, knee, shoulder, and elbow, and its products are sold in both domestic and international markets [1]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Spring Medical (01858.HK) by 108,800 shares on January 16, with a total net reduction of 1,034,000 shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have reduced their holdings on 10 occasions, resulting in a cumulative net reduction of 3,080,500 shares [1] - As of now, southbound funds hold 41,372,600 shares of Spring Medical, accounting for 43.47% of the company's total issued ordinary shares [1] Group 2 - Spring Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices in China [1] - The company's main products include joint prosthetics and spinal implant products, covering major human joints such as hip, knee, shoulder, and elbow [1] - The spinal implant products consist of a complete range of spinal fixation systems, and the company's products are exported to various countries and regions including Asia, South America, Africa, Oceania, and Europe [1]

Group 1 - The core viewpoint of the news is that Spring Medical has shown significant financial performance and trading activity, with a notable increase in revenue and net profit year-on-year [2][3] - On January 14, Spring Medical's stock rose by 1.18%, with a trading volume of 154 million yuan, and a net financing purchase of 1.73 million yuan, indicating strong investor interest [1] - As of January 14, the total margin balance for Spring Medical was 42.55 million yuan, with a financing balance of 42.22 million yuan, representing 0.55% of the circulating market value, which is at a high level compared to the past year [1] Group 2 - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] - The company reported a revenue of 756 million yuan for the first nine months of 2025, reflecting a year-on-year growth of 48.75%, and a net profit of 192 million yuan, which is a 213.21% increase compared to the previous year [2] - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [3]

Group 1 - The core viewpoint of the news is that Spring Medical has seen a stock price increase of 5.44%, reaching 28.11 yuan per share, with a total market capitalization of 10.782 billion yuan [1] - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [1] - The company's main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems, with 99.89% of revenue coming from medical device products [1] Group 2 - Among the top circulating shareholders of Spring Medical, a fund under China Europe Fund, specifically the China Europe Prosperity Selected Mixed A Fund (020876), has entered the top ten shareholders, holding 2.8326 million shares, which is 0.74% of the circulating shares [2] - The China Europe Prosperity Selected Mixed A Fund has achieved a year-to-date return of 8.28% and a one-year return of 60.79%, ranking 1417 out of 8840 and 1171 out of 8094 respectively [2] - The fund manager, Zhang Xueming, has been in position for 1 year and 268 days, with the fund's total asset size at 6.741 billion yuan and a best return of 79% during his tenure [3]

Core Viewpoint - Spring Medical has shown a significant increase in stock price and trading volume, indicating positive market sentiment towards the company and its growth potential in the orthopedic medical device sector [1]. Company Overview - Spring Medical is a leading domestic manufacturer of orthopedic medical devices, focusing on the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2][5]. - The company’s main products include joint prosthetics for the hip, knee, shoulder, and elbow, as well as a full range of spinal internal fixation systems [2][5]. - Spring Medical is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong market position and innovation capabilities [3]. Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a substantial increase of 213.21% [8]. - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [8]. Market Position and Shareholder Information - As of September 30, 2025, the number of shareholders in Spring Medical increased by 4.12% to 6,164, while the average number of circulating shares per person decreased by 3.95% [8]. - Notable institutional shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Fund, indicating growing interest from institutional investors [9]. Technical Analysis - The average trading cost of the stock is 23.50 yuan, with recent buying activity observed, although the strength of this accumulation is not strong [6]. - The stock price is approaching a resistance level of 26.41 yuan, suggesting potential for a price correction if this level is not surpassed [6].

Group 1 - The core viewpoint of the news is that Spring Medical has seen a stock price increase of 5.42%, reaching 26.06 CNY per share, with a total market capitalization of 9.996 billion CNY as of the report date [1] - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [1] - The company's revenue composition is primarily from medical device products, accounting for 99.89%, with a minor contribution from other sources at 0.11% [1] Group 2 - Among the top circulating shareholders of Spring Medical, a fund under China Europe Fund, specifically the China Europe Prosperity Selected Mixed A (020876), has entered the top ten shareholders, holding 2.8326 million shares, which is 0.74% of the circulating shares [2] - The China Europe Prosperity Selected Mixed A fund has achieved a year-to-date return of 7.47% and a one-year return of 63.55%, ranking 1811 out of 8836 and 1302 out of 8091 respectively [2] - The fund manager, Zhang Xueming, has been in position for 1 year and 266 days, with the fund's total asset size at 6.741 billion CNY and a best return of 79% during his tenure [3]

Group 1 - The core viewpoint of the news is that Spring Medical has shown a positive stock performance with a year-to-date increase of 12.04% and significant growth in revenue and net profit for the first nine months of 2025 [2][3]. - As of January 13, Spring Medical's stock price was 25.40 CNY per share, with a market capitalization of 9.743 billion CNY and a trading volume of 41.034 million CNY [1]. - The company specializes in the research, production, and sales of orthopedic medical devices, primarily focusing on joint prosthetics and spinal implants, with a revenue composition of 99.89% from medical device products [2]. Group 2 - For the first nine months of 2025, Spring Medical achieved a revenue of 756 million CNY, representing a year-on-year growth of 48.75%, and a net profit of 192 million CNY, which is a 213.21% increase compared to the previous year [3]. - The company has distributed a total of 440 million CNY in dividends since its A-share listing, with 390 million CNY distributed over the last three years [4]. - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [3].